Search

Your search keyword '"N., Dibiase"' showing total 2 results
Start Over Author "N., Dibiase" Journal european review for medical and pharmacological sciences
2 results on '"N., Dibiase"'

1. TNF-alpha blockade induce clinical remission in patients affected by polymyalgia rheumatica associated to diabetes mellitus and/or osteoporosis: a seven cases report

Author

A, Migliore, U, Massafra, E, Carloni, C, Padalino, S, Martin Martin, F, Lasaracina, N, Dibiase, A, Alimonti, and M, Granata

Subjects
Aged, 80 and over, Tumor Necrosis Factor-alpha, Remission Induction, Antibodies, Monoclonal, Infliximab, Diabetes Mellitus, Type 1, Treatment Outcome, Diabetes Mellitus, Type 2, Polymyalgia Rheumatica, Antirheumatic Agents, Humans, Osteoporosis, Female, Aged
Abstract

Polymyalgia rheumatica (PMR) is a chronic inflammatory condition of the elderly, characterized by aching and morning stiffness in the cervical region, shoulders and pelvic girdles. A steroid treatment course of 6-24 months is often required, but, due to important side effects, it is troublesome if the PMR patient is also affected by diabetes mellitus (DM) and/or osteoporosis. Aim of our study is to test anti-TNF alpha treatment as a steroid sparing tool in PMR patients affected by DM or osteoporosis. In particular, we hypothesise that TNF alpha blockade can be useful not only in remission maintaining, but also in the induction of clinical remission without corticosteroids in this kind of patients. In a six months follow up, patients had clinical improvement, confirmed by physical medical examination, and a statistically significant reduction in ESR and CRP mean values. Anti-TNF alpha treatment was well tolerated by all patients. These preliminary data suggest than Infliximab can be useful in the treatment of PMR patients, not only for steroid sparing purposes, but also as first line therapy in PMR patients with severe comorbidity, such as diabetes mellitus or osteoporosis.

Published
2006

2. TNF-alpha blockade induce clinical remission in patients affected by polymyalgia rheumatica associated to diabetes mellitus and/or osteoporosis: a seven cases report.

Author

Migliore A, Massafra U, Carloni E, Padalino C, Martin Martin S, Lasaracina F, Dibiase N, Alimonti A, and Granata M

Subjects
Aged, Aged, 80 and over, Antirheumatic Agents therapeutic use, Female, Humans, Infliximab, Polymyalgia Rheumatica complications, Remission Induction, Treatment Outcome, Tumor Necrosis Factor-alpha antagonists & inhibitors, Antibodies, Monoclonal therapeutic use, Diabetes Mellitus, Type 1 complications, Diabetes Mellitus, Type 2 complications, Osteoporosis complications, Polymyalgia Rheumatica drug therapy, Tumor Necrosis Factor-alpha immunology
Abstract

Polymyalgia rheumatica (PMR) is a chronic inflammatory condition of the elderly, characterized by aching and morning stiffness in the cervical region, shoulders and pelvic girdles. A steroid treatment course of 6-24 months is often required, but, due to important side effects, it is troublesome if the PMR patient is also affected by diabetes mellitus (DM) and/or osteoporosis. Aim of our study is to test anti-TNF alpha treatment as a steroid sparing tool in PMR patients affected by DM or osteoporosis. In particular, we hypothesise that TNF alpha blockade can be useful not only in remission maintaining, but also in the induction of clinical remission without corticosteroids in this kind of patients. In a six months follow up, patients had clinical improvement, confirmed by physical medical examination, and a statistically significant reduction in ESR and CRP mean values. Anti-TNF alpha treatment was well tolerated by all patients. These preliminary data suggest than Infliximab can be useful in the treatment of PMR patients, not only for steroid sparing purposes, but also as first line therapy in PMR patients with severe comorbidity, such as diabetes mellitus or osteoporosis.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results